Skip to main content
Donate

Agilis Biotherapeutics and Dr. Edwin Weeber Enter Into Worldwide Licensing Agreement For Angelman Syndrome Gene Therapy

“It has been our hope from day one that the pharmaceutical industry would recognize the promise for developing therapeutics for Angelman Syndrome, we are thrilled that Agilis has come forward to invest in this promise and invest in an amazing researcher, which will move us closer to the goals of treatments for this disorder.” ~  Rebecca Burdine Ph.D., Assoc Professor at Princeton University and Chief Science Officer for FAST. Read more about the partnership with Dr. Edwin Weeber and Agilis Biotherapeutics…

Disclaimer

This website contains information for a broad audience and may include information on current and upcoming programs that are not yet approved or accessible The information provided is for general informational purposes only and is not intended as medical advice, diagnosis, or treatment. While FAST strives to provide accurate and up-to-date information, the content on this site may not always reflect the most current research or clinical guidelines. The inclusion of clinical trial information, treatments or specific healthcare providers does not imply endorsement, recommendation or guarantee of safety, efficacy, or availability. Reliance on any information provided by this website is solely at your own risk. FAST disclaims any liability for any errors or omissions in the information provided or for any decisions made based on this information. For personalized medical advice or specific health concerns including participation in any clinical trial, please consult a qualified healthcare professional.